The largest database of trusted experimental protocols

14 protocols using psuper puro vector

1

Generating BDNF shRNA Knockdown Constructs

Check if the same lab product or an alternative is used in the 5 most similar protocols
A BDNF shRNA construct was designed using an online design program from MIT (http://sirna.wi.mit.edu/home.php). The 19-nucleotide hairpin-type shRNAs with a 9-nucleotide loop were cloned into the pSUPER-puro vector (OligoEngine, USA) according to manufacturers’ protocol. shRNA sequences are included in the Supplementary File. SVOG cells were transfected using Lipofectamine 2000 with the pSuper-puro shRNA constructs and selected for 4 days in media containing 2 μg/ml puromycin. The cells were collected and screened by western blot for target expression knockdown.
+ Open protocol
+ Expand
2

Targeting Apoptosis Regulators in TNBC

Check if the same lab product or an alternative is used in the 5 most similar protocols
Retrovirus-encoded short-hairpin RNAs (shRNAs), shNOXA, shBIM, and shPUMA, were cloned into the pSuper puro vector (Oligoengine; Seattle, WA, USA). The target sequences were as follows: 5′-GGAAACGGAAGATGGAATA-3′ (shNOXA#1), 5′-GCTACTCAACTCAGGAGAT-3′ (shNOXA#2), 5′-CTACCTCCCTACAGACAGA-3′ (shBIM), 5′-GGGTCCTGTACAATCTCAT-3′ (shPUMA). Lentiviral shRNA-expressing constructs were cloned into the plko.1 vector (Addgene; Cambridge, MA, USA). The target sequences were as follows: 5′-CCAGCCAGAAAGCACTACAAT-3′ (sh-KLF4), 5′-GAACTGCACTTCAGCAATAAT-3′(sh-BNIP3), and 5′-CCTAAGGTTAAGTCGCCCTCG-3′ (sh-control). The constructs were transfected into 293T packaging cells along with the packaging plasmids (Addgene) and the lentivirus-containing supernatants were used to transduce TNBC cells. Retroviral or lentiviral infection was performed as previously described [40 (link)]. Infected cells were selected using 1 μg/mL puromycin (Sigma-Aldrich) for 3 days.
siRNA transfections were performed using Opti-MEM and Lipofectamine RNAi Max (Invitrogen, Waltham, MA, USA) with a final siRNA concentration of 10 μM siRNA. Cells were transfected at a concentration of 10 nM for 24 h. The siRNAs used in this study were silencer negative control (4390843) and si-ATF4 (s1704) (Silencer Select siRNAs from Ambion, Austin, TX, USA).
+ Open protocol
+ Expand
3

Combinatorial shRNA Knockdown of Pluripotency Factors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Gene-specific 19nt shRNAs were designed based on a previously described algorithm using an in-house Perl script [49] (link). All shRNA sequences were BLASTed to ensure specificity. Synthesized oligomers were annealed and ligated into the pSuper.puro vector (Oligoengine). To make the Oct4/Nanog/Esrrb combinatorial shRNA constructs, ClaI-XhoI sites were used to insert H1-shRNA cassettes digested with BstBI-XhoI. The shRNA encoding sequences are: Oct4– GAAGGATGTGGTTCGAGTA (shRNA_#1) and GCGAACTAGCATTGAGAAC (shRNA_#2), Nanog– GAACTATTCTTGCTTACAA, Esrrb– GATTCGATGTACATTGAGA and Jarid2 – TCACTGTCCTCCCAAATAA.
+ Open protocol
+ Expand
4

Generation of Per1-3 Constructs and RNAi

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mouse Per1-3 cDNAs were kind gifts from Dr. T. Takumi (RIKEN, Saitama, Japan), and cloned into pCAG-Myc vector (Addgene Inc., Cambridge, MA). For RNAi experiments, following target sequences were inserted into pSuper-puro vector (OligoEngine, Seattle, WA): mPer3#1, CAGTAACGACAAAGACATA (1170-1188); mPer3#2, CCTAGATGCTCTTAACTAT (225-243). Numbers indicate the positions from Per3 translational start sites. We named these vectors as pSuper-mPer3#1 and #2. For the control RNAi experiments, we used pSuper-Luc designed against luciferase (CGTACGCGGAATACTTCGA). To generate RNAi-resistant Per3, Per3-R, silent mutations were introduced, as underlined, in the target sequence (GAGCAATGATAAGGATATC in Per3#1). All constructs were verified by DNA sequencing. pCAG-histone 2B-EGFP was used to label chromosomes41 (link).
+ Open protocol
+ Expand
5

shRNA cDNA Construct Generation for RNAi

Check if the same lab product or an alternative is used in the 5 most similar protocols
ShRNA cDNA constructs for RNAi expression were directionally ligated into the BglII/XhoI sites into pSUPER-Puro vector (OligoEngine, Seattle, WA).36 (link) The shRNA design and schematic are shown below with target sequences (Fig. 2C). ShRNAs are expressed from the human H1 promoter (strong extragenic RNA Pol-III).
Oligodeoxynucleotides were synthesized by Sigma GenoSys (The Woodlands, TX) or Integrated DNA Technologies (Coralville, IA).
+ Open protocol
+ Expand
6

mLin7A Targeted RNAi Silencing

Check if the same lab product or an alternative is used in the 5 most similar protocols
Modifications of the pSUPER-puro vector (OligoEngine, Seattle, WA, USA) were designed to target two distinct coding sequences in mLin7A: pSUPER-mLin7A#1 targets 5′-GTGTATCAATACATGCATG-3′, 202–220; and pSUPER-mLin7A#2 targets 5′-GTTGAACTGCCAAAGACTG-3′, 325–343 (numbers indicate the position from the transcription start site). As an RNAi-resistant version of mLin7A, we used the human ortholog hLin7, in which the target sequence against pSUPER-mLin7A#1 contains a mismatched nucleotide (5′-GTGTATCAATATATGCATG-3′) as marked with an underline. The target sequences for pSuper-mLin7A#1 and #2 contain mismatched nucleotides when compared to the corresponding sequences in mLin7B (targets 5′-GTGTATGAACAGCTCTATG-3′, 5′-GTGGAACTACCGAAGACTG-3′), respectively, as marked with underlines.
+ Open protocol
+ Expand
7

Knockdown of Apoptosis Regulators in Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The retrovirus-encoding hairpin short-hairpin RNA (shRNA) vectors for NOXA, PUMA, BIM, BID, and MULE were cloned into the pSuper puro vector (Oligoengine, Seattle, WA, USA). The target sequences were as follows: 5′-GGAAACGGAAGATGGAATA-3′ (sh-NOXA), 5′-CTACCTCCCTACAGACAGA-3′ (sh-BIM), 5′-GGGTCCTGTACAATCTCAT-3′ (sh-PUMA), 5′-GGGATGAGTGCATCACAAA-3′ (sh-BID), 5′-TGCCGCAATCCAGACATAT-3′ (sh-MULE), 5′- GCACCTCTGCCACCGGATG-3′ (sh-ATF3 #1), 5′-GCAGAAAGTTCAACTTCCA-3′ (sh-ATF3 #2), and 5′-GCAGCTCATGCAACATCAT-3′ (sh-CREB). Retroviral infection was performed as previously described [13 (link)]. The lentiviral shRNA shKLF4-expressing constructs were cloned into the plko.1 vector (Addgene, Cambridge, MA, USA). The target sequences were as follows: 5′-CCAGCCAGAAAGCACTACAAT-3′ (sh-KLF4) and 5′-CCTAAGGTTAAGTCGCCCTCG-3′ (sh-control). Lentiviral infection was performed as previously described [27 (link)]. Infected cells were selected using 1 μg/mL puromycin (Sigma-Aldrich) for three days.
+ Open protocol
+ Expand
8

Construction of Wdr45 Expression Constructs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mouse (m)Wdr45 was amplified by PCR and subcloned into pCAG-Myc vector (Addgene Inc., Cambridge, MA). For RNAi experiments, following target sequences were inserted into pSuper-puro vector (OligoEngine, Seattle, WA): mWdr45#1, CAAGAAAGCTGTTTGAGTT (395–413); mWdr45#2, CCCTTATTCGTCTCTTTGA (644–662). Numbers indicate the positions from Wdr45 translational start sites. We named these vectors as pSuper-Wdr45#1 and #2. For the control RNAi experiments, pSuper-H1.shLuc designed against luciferase (CGTACGCGGAATACTTCGA) was used. To generate RNAi-resistant Wdr45, Wdr45R, silent mutations were introduced, as underlined, in the target sequence (CAAGGAAATTATTCGAGTT in mWdr45#1). The Wdr45 mutant related to BPAN pathogenicity7 (link), c.700C > T/p.(Arg234*) (Wdr45-Rstop), was prepared using KOD-Plus Mutagenesis kit (Toyobo Inc., Osaka, Japan). Likewise, another mutant with a single amino acid substitution, c.439G > T/p.(Gly167Val) (Wdr45GV), was prepared. For antibody absorption experiments, full length Wdr45 was subcloned into pMal-p2, expressed in E. coli and affinity-purified as a recombinant protein according to the manufacturer’s instruction (New England BioLabs Inc., Ipswich, MA). All constructs were verified by DNA sequencing.
+ Open protocol
+ Expand
9

Generating Stable Rab7 Knockdown Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Stable Rab7 knockdown cells were generated from a polyclonal population as described previously (Benlimame et al., 2005). The target shRNA sequence for Rab7 (GenBank/EMBL/DDBJ, accession no. NM_004637.5) was 5′-CTGCTGCGTTCTGGTATTTGA-3′ (targeting nucleotide 478-498). This sequence was cloned as an inverted repeat into pSUPER.puro vector according to the manufacturer's instructions (OligoEngine).
+ Open protocol
+ Expand
10

RNAi-Resistant SIL1 and HSPA5 Constructs

Check if the same lab product or an alternative is used in the 5 most similar protocols
pSUPER-puro vector (OligoEngine, Seattle, WA, USA) was designed to target 2 distinct coding sequences in mSIL1 (pSUPER-mSIL1#1: 5′-GCTCCAACAAGAAGACAAA-3′, 309–327; pSUPER-mSIL1#2: 5′-GGTTGCTGCGCTCTTTGAT-3′, 618–636) and mHSPA5 (pSUPER-mHSPA5#1: 5′-GAACATCCTTGTGTTTGAC-3′, 657–675; pSUPER-mHSPA5#2: 5′-GAAATCTGATATTGATGAA-3′, 1059–1077). Numbers indicate the position from transcription start sites. As RNAi-resistant versions of SIL1 and HSPA5, we used their human orthologs where the target sequences contain mismatched nucleotides.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!